Fig. 3From: A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozoleIndividual plasma concentration–time profiles of letrozole after multiple oral administrations of 30, 40 or 50 mg afatinibBack to article page